This review focuses on the current and potential future treatment of NASH and the clinical practice in fatty liver transplantation, highlights its limitations and optimal allocation, and summarizes the advances of experimental...
Although peripheral blood stem cells (PBSC) have worldwide become the predominant source of progenitor cells for hematopoietic stem cell transplantation (HSCT), debate about their role compared with bone marrow (BM)...
Graft microvasculature is a major target of donor-specific antibodies (DSA) and endothelial damage is a direct evidence of antibody-mediated rejection (ABMR). Using immunohistochemistry, we analyzed the expression...
ILUVIEN is indicated for the treatment of vision impairment associated with chronic diabetic macular oedema, (DMO) considered insufficiently responsive to available therapies (see Section 5.1). ILUVIEN is indicated for prevention of relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (see Section 5.1).
Abbott is communicating to physicians about a field corrective action related to the HeartMate 3 Left Ventricular Assist Device (LVAD)....
GLIADEL Implant is indicated for the treatment of adult patients with newly-diagnosed high-grade malignant glioma as an adjunct to surgery and radiation. GLIADEL Implant is indicated as an adjunct to surgery for the treatment of adult patients with recurrent histologically proved glioblastoma multiforme and for whom surgical resection is indicated.
The FDA has approved the Raindrop Near Vision Inlay, from Revision Optics, a device implanted in the cornea (the clear,...
Sixmo is indicated for substitution treatment for opioid dependence in clinically stable adult patients who require no more than 8 mg/day of sublingual buprenorphine, within a framework of medical, social and psychological treatment.
This Clinical Practice Guideline (CPG) has been developed to assist physicians and other healthcare providers during the evaluation process of candidates for LT and to help them in the correct management of patients after LT.
Boston Scientific announced initial U.S. commercial performance results of the Watchman Left Atrial Appendage Closure (LAAC) Device during a late-breaking...